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Abstract
The classical antivenom therapy has appreciably reduced snakebite mortality rate and thus is the only savior drug available.
Unfortunately, it considerably fails to shield the viper bite complications like hemorrhage, local tissue degradation and
necrosis responsible for severe morbidity. Moreover, the therapy is also tagged with limitations including anaphylaxis,
serum sickness and poor availability. Over the last decade, snake venom metalloproteases (SVMPs) are reported to be the
primary component responsible for hemorrhage and tissue degradation at bitten site. Thus, antivenom inability to offset
viper venom-induced local toxicity has been a basis for an insistent search for SVMP inhibitors. Here we report the inhibitory
effect of compound 5d, an apigenin based molecule against SVMPs both in silico and in vivo. Several apigenin analogues are
synthesized using multicomponent Ugi reactions. Among them, compound 5d effectively abrogated Echis carinatus (EC)
venom-induced local hemorrhage, tissue necrosis and myotoxicity in a dose dependant fashion. The histopathological study
further conferred effective inhibition of basement membrane degradation, and accumulation of inflammatory leucocytes at
the site of EC venom inoculation. The compound also protected EC venom-induced fibrin and fibrinogen degradation. The
molecular docking of compound 5d and bothropasin demonstrated the direct interaction of hydroxyl group of compound
with Glu146 present in hydrophobic pocket of active site and does not chelate Zn2+. Hence, it is concluded that compound
5d could be a potent agent in viper bite management.
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Introduction
Snake envenomation is a neglected tropical disease affecting a
large population residing in resource poor settings that are away
from the primary health care centers [1,2]. Most snakebite
incidents in tropical countries are inflicted by vipers, among which
Echis carinatus (EC) accounts for thousands of deaths and much
more morbidity in Asia [3–5]. A maximum number of viper bite
survivors suffer from permanent physical disabilities and psycho-
logical problems. EC envenomation causes remarkable local tissue
damage including hemorrhage, myonecrosis, edema, and blister-
ing along with systemic effects such as systemic hemorrhage of
vital organs, hormonal imbalance, altered hemostasis, renal
malfunction and hypotension [6,7]. These pathological disorders
comprise a cascade of events attributed to the combined action of
extracellular matrix (ECM) degrading enzymes and target specific
toxins/enzymes of EC venom [8].
Though the mortality rate due to snakebite is reduced markedly
with the use of antivenoms, the therapy is tagged with limitations
including anaphylaxis, serum sickness and poor availability [9].
Moreover, the major hurdle in the viper bite management is the
incompetence of antivenom against debilitating local manifesta-
tions. A large amount of evidence exists reporting the persistent
local tissue necrosis and damage at the bitten region even after the
neutralization of systemic toxicity by classic antivenom therapy
and has emerged as a post-medicated risk [10,11]. The major
components responsible for the notorious local tissue damage and
systemic hemorrhage following viper bite are snake venom
metalloproteases (SVMPs). These enzymatic toxins are generally
denoted as ‘‘spreading factors’’ as they facilitate the easy diffusion
of target specific toxins/enzymes into circulation by degrading the
proteins of basement membrane and the connective tissues
surrounding blood vessels [12,13]. Thus, inhibition of SVMPs
not only blocks the local toxicity, but also increases the survival
time of the victim by reducing the dispersal of systemic toxins.
Consequently, inhibition of SVMPs is reflected as a rate limiting
step in viper bite management. Based on these facts, basic
researchers and medical practitioners have considered SVMPs as
the prime target to diminish the local tissue damage and systemic
hemorrhage [14,15].
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e106364
In view of the frightening encumbrance of antivenoms, there is
a need for designing new therapeutic molecules to neutralize the
continued local tissue destruction and life threatening systemic
complications. So far, several studies have reported the inhibition
of SVMPs and its pathological effects by different chelating agents,
synthetic and bioactive molecules including terpenoids, sterols,
polyphenols and flavonoids [15–17]. These molecules show
inhibition towards different class of SVMPs to a varied extent.
Apigenin belongs to flavone class of compounds and is known to
inhibit several clinically important enzymes and cure pathological
disorders. In the recent past, several studies reported the
mitigation of matrix metalloproteinases (MMPs) expression by
apigenin in target cells, which is induced by several agents such as
carcinogens, ultraviolet A (UVA 320–400 nm), phorbol myristate
acetate (PMA), interleukin-1 beta (IL-1b) and tumor necrosis
factor-alpha (TNF-a) [18–21]. Further, inhibitory action of
apigenin or apigenin structural analogues against cutaneous
inflammation and infection-induced inflammation is also demon-
strated [22,23]. However, no study claims the SVMP inhibitory
efficacy of apigenin or derivatives having apigenin nucleus.
The current study therefore focuses on derivatives with apigenin
nucleus as potential inhibitors of SVMPs. To accomplish this
challenge, we have utilized the multi-component reaction
approach to synthesize the library of apigenin based small
molecules to target SVMP-induced pathological effects in exper-
imental animals. Additionally, in silico molecular interaction data
between lead compound and SVMP is also demonstrated using
the Accelrys Discovery Studio software [24].
Materials and Methods
Synthesis and characterization of various apigenin structural
analogues were provided as supplementary data (Data S1 and
Table S1)
Chemicals
Echis carinatus venom (EC venom) was obtained from Irula
Snake Catchers, Chennai, India. Gelatin (Type A from porcine
skin), fibrinogen (from human plasma fraction I) were purchased
from Sigma chemicals, St. Louis, USA. Lactate dehydrogenase
(LDH) and Creatine phosphokinase (CPK) commercial kits were
purchased from AGAPEE Diagnostics Ltd. Kerala, India. All
other chemicals were of analytical grade purchased from Sisco
Research Laboratories (SRL), Mumbai, India.
Experimental animals
Adult Swiss Albino mice weighing 20–25 g were used for
pharmacological studies. Animals were collected from University
Central Animal Facility and housed under a controlled environ-
ment. All experiments were approved by the Intuitional Animal
Ethical Committee (UOM/IAEC/06/2011), Department of
Studies in Zoology, University of Mysore, Mysore, and were in
accordance with the guidelines of the Committee for the Purpose
of Control and Supervision of Experiments on Animals
(CPCSEA). Besides, experiment involving healthy human blood
plasma was approved by the Institutional Human Ethical
Committee (IHEC-UOM No. 75/Ph.D/2012–13).
Molecular Docking studies
The co-crystal structure of the SVMP with bound POL647, a
pepditomimetic inhibitor of bothropasin was used for structure-
based molecular docking studies [25]. The software InsightII from
Accelrys was used to obtain a full set of tools for molecular
modeling, which includes molecular graphics and forcefield-based
simulations as reported previously [26]. The co-crystal structure of
SVMP and POL647 was retrieved (PDBID: 3DSL). The
molecular modeling was achieved with commercially available
InsightII, Discovery Studio (DS) Version 2.5 software packages.
Before performing CDOCKER protocol of DS, the 3D structure
of SVMP was cleaned and the size and spatial orientation of the
active site was identified by considering the tools such as selecting
structure molecule as receptor and binding site or the sphere was
made using the available programmes of the software. All of the
calculations were performed using the CHARMM force field.
Each energy-minimized final docking position of the individual
apigenin structural analogues was evaluated using the interaction
score function in the CDOCKER module of DS version 2.5.
Based on the low CDOCKER energy value, compound 5d was
selected for further studies.
Hemorrhagic activity
Hemorrhagic activity was determined according to the method
of Kondo et al. [27]. Different doses of compound 5d (1:0, 1:1, 1:5
and 1:10 ratio; venom: compound; w/w) were pre-incubated with
EC venom [2 mg; minimum hemorrhagic dose (MHD), which is
defined as the amount of venom that produces a hemorrhagic
diameter of 10 mm] in a total volume of 50 mL PBS (10 mM,
pH 7.4) at 37uC for 10 min. The pre-incubated samples were then
injected intradermally into groups of mice (n = 5) independently
and respective control groups were included. For independent
injection experiment, mice (n = 5) were intradermally injected with
2 mg of EC venom first, which was preceded by compound 5d
injection at the same site in the ratio 1:10 (venom: compound; w/
w) at different time intervals (0, 2.5, 5, 7.5 and 10 min). The
compound 5d dose was selected based on the results obtained in
pre-incubation study of venom with compound 5d (twice the
concentration of complete inhibition of hemorrhage). After 3 h,
the experimental mice were anaesthetized and the dorsal patch of
skin was removed; the inner surface was observed for the
hemorrhage and the diameter of the hemorrhagic spot was
measured and photographed. Further, the skin tissues were
processed for histopathology.
Gelatinolytic activity
In order to determine the effect of compound 5d on gelatinolytic
activity of EC venom, substrate gel assay was carried out as
described by Heussen and Dowdle [28] with minor modifications.
Briefly, gelatin was co-polymerized with a final concentration of
1% in to native-PAGE (10%). EC venom (3 mg) in the presence
and absence of compound 5d was electrophoresed using basic-
PAGE at 100 V at room temperature. The electrophoresed gel
was incubated overnight at 37uC in 50 mM Tris-HCl buffer,
pH 7.6 containing 150 mM NaCl, 10 mM CaCl2 and then
stained with coomassie brilliant blue R-250. For inhibition studies,
EC venom (3 mg) was pre-incubated independently with different
doses of compound 5d (1:0, 1:1, 1:2, 1:5, 1:10, 1:25 and 1:50 ratio;
venom: compound; w/w) for 10 min at 37uC prior to electropho-
resis. SVMP activity was detected as unstained translucent bands
against dark blue back ground.
Caseionolytic activity
To determine the effect of compound 5d on caseinolytic activity
of EC venom, substrate gel assay was carried out as described by
Nagaraju et al. [29]. Briefly, casein was co-polymerized with a
final concentration of 0.2% in to native-PAGE (10%). EC venom
(3 mg) in the presence and absence of compound 5d was
electrophoresed using basic-PAGE at 100 V at room temperature.
The electrophoresed gel was incubated overnight at 37uC in
Inhibition of SVMPs by Apigenin Structural Analogues
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50 mM Tris-HCl buffer, pH 7.6 containing 150 mM NaCl,
10 mM CaCl2 and then stained with coomassie brilliant blue R-
250. For inhibition studies, EC venom (3 mg) was pre-incubated
independently with different doses of compound 5d (1:0, 1:1, 1:2,
1:5, 1:10, 1:25 and 1:50 ratio; venom: compound; w/w) for
10 min at 37uC prior to electrophoresis. Caseinolytic activity was
detected as unstained translucent bands against dark blue back
ground.
UV-VIS Spectral Study
The interaction between cations such as Zn2+ and Ca2+ with
compound 5d was studied by UV-VIS absorption spectroscopic
scanning. Compound 5d (1 mM) was incubated with different
concentrations of ZnCl2 and CaCl2 (0 to 2 mM) in 1 mL of PBS
(10 mM, pH 7.4) and scanned with the wavelength range between
200–300 nm, using Beckman Coulter DU-730 spectrophotometer.
Myotoxicity and myonecrosis
Effect of compound 5d on EC venom-induced myotoxicity was
determined by following the method of Gutierrez et al. [30]. 5 mg
of EC venom was pre-incubated with or without different doses of
compound 5d (1:5, 1:10 and 1:25; venom: compound; w/w) in a
total reaction volume of 50 mL saline at 37uC for 10 min. Then
the samples were injected intramuscularly into the right thigh of
mice (n = 5). For independent injection experiment, mice (n = 5)
were intramuscularly injected with EC venom later at different
time intervals (0, 2.5, 5, 7.5 and 10 min) mice were injected with
compound 5d at the ratio of 1:50 (venom: compound; w/w) at the
same site where venom was injected. The mice were anaesthetized
and blood was collected by cardiac puncture. The thigh muscles
were observed for damages, dissected and further processed for
histopathology. Cytoplasmic marker enzymes lactate dehydroge-
nase (LDH) and creatine phosphokinase (CPK) were assessed in
serum using AGAPEE diagnostic kits. Activities were expressed as
unit/L.
Edema inducing activity
The edema inducing activity was assessed according to the
method of Yamakawa et al. [31]. EC venom [0.6 mg; minimum
edema dose (MED), which is defined as the amount of protein
required to cause an edema ratio of 120%] was pre-incubated with
or without different doses of compound 5d (1:1, 1:5, 1:10 and 1:25
ratio; venom: compound; w/w) in a total reaction volume of 20 mL
saline at 37uC for 10 min. Later on the samples were injected to
groups of five mice in to the right footpads. The left footpad
received saline, which served as control. Mice were sacrificed after
1 hr of sample injection and legs were dissected off at the ankle
joint. An increase in weight due to edema was calculated as the
edema ratio, which equals the weight of the edematous leg6100/
weight of control leg.
Coagulant activity
The plasma coagulation property was determined according to
the method of Condrea et al. [32]. Healthy human citrated plasma
(200 mL) was incubated with 0.5 mg of EC venom and the clotting
time was recorded after the addition of calcium chloride against a
light source. Control tubes included citrated plasma incubated
with PBS and calcium chloride or compound 5d alone. For
inhibition studies, EC venom (0.5 mg) was pre-incubated with
different doses of compound 5d (1:1, 1:5, 1:10, 1:25 and 1:50 ratio;
venom: compound; w/w).
Fibrinogenolytic activity
Fibrinogenolytic activity was determined according to the
method of Ouyang and Teng [33]. Human plasma fibrinogen
(50 mg) was incubated with 0.2 mg of EC venom, which was pre-
incubated with or without different doses of compound 5d (1:1,
1:5, 1:10, 1:25 and 1:50 ratio; venom: compound; w/w) in 40 mL
reaction volume of 10 mM Tris-HCl buffer pH 7.4, containing
10 mM NaCl at 37uC for 10 min. The reaction was terminated
after 30 min by adding 20 mL denaturing buffer containing 1 M
urea, 4% SDS and 4% b-mercaptoethanol. It was analyzed in
10% SDS-PAGE and the protein pattern was visualized by
staining the gel with 0.1% coomassie brilliant blue R-250.
Fibrinolytic activity
Fibrinolytic activity was determined using fibrin clot as a
substrate. The fibrin clot was incubated with EC venom (0.2 mg) in
40 mL of 10 mM Tris-HCl buffer pH 7.4, containing 10 mM
NaCl. The reaction was terminated after 30 min by adding 20 mL
denaturing buffer containing 1 M urea, 4% SDS and 4% b-
mercaptoethanol. An aliquot of 20 mL was analyzed in 10% SDS-
PAGE and the protein pattern was visualized by staining the gel
with 0.1% coomassie brilliant blue R-250. For inhibition studies,
EC venom (0.2 mg) was pre incubated with different doses of
compound 5d (1:1, 1:5, 1:10, 1:25 and 1:50 ratio; venom:
compound; w/w) at 37uC for 10 min.
Histopathological studies
Skin and thigh muscle tissues were dissected out and fixed
overnight in Bouin’s solution. The tissue samples were dehydrated
by treating with different grades of alcohol and chloroform:
Figure 1. Schematic representation for the synthesis of apigenin structural analogues.
doi:10.1371/journal.pone.0106364.g001
Inhibition of SVMPs by Apigenin Structural Analogues
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e106364
alcohol mixture. The processed tissue samples were embedded in
molten paraffin wax, and 4 mm thick sections were prepared using
microtome (Leica, Solms, Germany). The sections were stained
with hematoxylin and eosin dye and were observed under Axio
imager.A2 microscope and photographed.
Protein estimation
Protein estimation was performed according to the method of
Lowry et al. [34] using bovine serum albumin (BSA) as standard.
Statistical analysis
Unless otherwise specified, the results are expressed as mean
values 6 SEM of five independent experiments. The data were
compared by using analysis of variance (ANOVA) followed by the
Tukey ‘‘honestly significantly different’’ (HSD) post hoc analysis.
Significance was accepted for p,0.05 (*), p,0.01 (**) and p,
0.001 (***). a - significant compared to saline control and b -
significant compared to venom alone.
Figure 2. Stereo view of 3D structure of the SVMP (Bothropasin) showing molecular interaction with the compound 5d. The
interaction between the compound and active site residues are shown using a line representation colored by parent atoms except for carbon (green
color). The ligand is presented in the ball and stick form with their parent color except for carbon (white color). Hydrogen bonds are presented as
white dotted lines.
doi:10.1371/journal.pone.0106364.g002
Table 1. Computational analysis of binding of compounds towards SVMP.
Compounds -CDOCKER ENEGRY -CDOCKER Interaction Energy
5a 30.8968 40.7197
5b 25.7389 46.1391
5c 30.1536 40.9792
5d 24.9736 39.1561
5e 28.55 40.201
5f 26.3275 42.4749
5g 28.6251 40.0069
5h 31.6015 44.2579
5i 32.4109 43.3109
5j 34.4272 45.0507
POL647 22.45 41.39
GM6001 0.37831 39.495
doi:10.1371/journal.pone.0106364.t001
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Results
In the present study, we made an attempt to synthesize apigenin
based small molecules with a flexible substitution at second
position of the chroman moiety. A library of compounds was
prepared by multi-component Ugi reaction using various aromatic
amines, t-butyl-isocyanide and halo acetic acids (Fig. 1). The
structures of the products were deduced based on IR, LC-MS, 1H
NMR, and 13C NMR spectra (Table S1 and Data S1). During the
preparation of the title compounds, the protocol was found to be
effective with aromatic amines having electron donating groups
and also, the para-methyl-substituted amines proceeded in shorter
time. In contrast, the ortho-substituted amines took longer time to
undergo products, which is likely due to its steric properties.
Further, to examine the possible molecular interaction between
SVMP and synthesized apigenin analogues, in silico molecular
docking analysis were performed using Discovery Studio (DS)
Version 2.5. The crystal structure of bothropasin, class III SVMP
with the bound POL647 was used as a starting point. In order to
know the molecular interaction between apigenin structural
analogues and active site residues of bothropasin, molecular
docking studies were performed. The results confirmed that the
analogues showed high affinity towards active site residues with
varied CDOCKER energy. Among the tested compounds,
Figure 3. Effect of compound 5d on caseinolytic and gelatinolytic activities of EC venom. EC venom (3 mg) was pre-incubated separately
with varied doses of compound 5d (1:0; 1:1; 1:2; 1:5; 1:10; 1:25 and 1:50; venom: compound; w/w; Lane 1–7 respectively, Lane-8 represents 100 mg of
compound 5d alone) for 10 min at 37uC. Samples were electrophoresed on gels impregnated separately with (A) casein (0.2%) and (B) gelatin (1%) as
substrate. The gels were then processed as described in materials and methods section.
doi:10.1371/journal.pone.0106364.g003
Figure 4. Neutralization of hemorrhagic activity of EC venom by compound 5d. EC venom (2 mg) was pre-incubated separately with
various doses of compound 5d (1:0 to 1:10; venom: compound; w/w) in a total volume of 50 mL PBS for 10 min at 37uC. The samples were then
injected intradermally into experimental animals (n = 5) and the assay was performed as described in materials and methods section. Results are
expressed as repetitive pictures of three independent experiments.
doi:10.1371/journal.pone.0106364.g004
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compound 5d was found to interact effectively with the active site
of bothropasin with CDOCKER energy of 24.97 (Table 1). The
flavone group of compound 5d was found buried into the active
site grove via strong hydrogen bonding between the hydroxyl
group and Glu146 of hydrophobic pocket that connects with
Ile142 and His145 and other hydrophobic key amino acids, like
val141, Ile168, Gly170, Pro171, Thr172, and Ile173. Additionally,
acyl bromide tail of compound 5d formed hydrogen bonding with
residues of active site including Thr110, Ile111, and Gly112
(Fig. 2). The acyl bromide tail also formed hydrophobic
interaction with Gly108 and Pro109 residues. In addition, t-butyl
group of amine of compound 5d was staked stacking with Tyr113
residue. In order to compare the results with a known SVMP
inhibitors, POL647 and GM6001 were docked independently and
ligands showed binding affinity with CDOCKER energy 22.45
and 0.37 respectively (Table 1). Based on the CDOCKER energy
values, compound 5d was selected for further functional studies.
Effect of compound 5d on EC venom-induced proteolytic
activity
In order to evaluate the inhibitory efficacy of compound 5d on
proteolytic activities of EC venom, zymography was carried out.
Figure 3A and 3B represents the proteolytic activity of EC
venom on casein and gelatin substrates respectively; the appear-
ance of clear translucent bands against dark blue background
suggests the caseinolytic and gelatinolytic activities. In both the
cases, lane 1 represents the protease activity of EC venom in the
absence of compound 5d. The results reveal that EC venom has
SVMPs in a greater extent compared to serine proteases. Lane 2–7
represents the dose dependent inhibition of proteolytic activity by
compound 5d. Complete inhibition was observed at the 1:10
(venom: compound; w/w) ratio in both the cases. However,
compound alone (200 mg) did not show any proteolytic activity on
casein and gelatin.
Effect of compound 5d on EC venom-induced
hemorrhagic activity
The protective efficacy of compound 5d on EC venom-induced
hemorrhage was assessed both in pre-incubation and independent
injection experiments. Experimental mice were intradermally
injected with either PBS or EC venom, and then the size of
hemorrhage was measured 3 h post-injection. 2 mg of EC venom
induced a hemorrhagic halo of 11 mm. In case of pre-incubation
study, the EC venom-induced hemorrhage was dose dependently
inhibited by compound 5d and complete inhibition was found at
the ratio of 1:5 (venom: compound; w/w) (Fig. 4). On the other
hand, hemorrhage was significantly inhibited by compound (1:10,
w/w) when injected even after the time interval of 0, 2.5 and
5 min with a protection of 73%, 64% and 55% respectively in the
independent study. However, inhibition was not significant
beyond 7.5 min delay in compound 5d administration (Table 2).
These results confirmed that pre-treatment with compound largely
Table 2. Effect of compound 5d on EC venom-induced hemorrhage in an independent injection experiment.
Groups (n=5) Delay in compound 5d administration (min) Diameter of hemorrhagic spot (mm) (mean ± SEM) Inhibition (%)
Group I - Saline control - 0 -
Group II - Venom alone - 1163 -
Group - III 0 361 73**
Group - IV 2.5 462 64**
Group - V 5.0 562 55**
Group - V 7.5 863 27*
Group - VII 10.0 1062 9
EC venom (2 mg) was intradermally injected to the group of mice (n = 5) followed by injection of compound 5d (20 mg) at various time intervals (0, 2.5, 5, 7.5 and 10 min)
to the same site where venom had been injected, and then the respective assay was performed as described in the materials and methods section. Data are presented
as the mean 6 SEM, ** p,0.01; * p,0.05.
doi:10.1371/journal.pone.0106364.t002
Figure 5. Light microphotograph of mice skin sections and blood vessels. EC venom (2 mg) was pre-incubated separately with compound
5d for 10 min at 37uC. The samples were injected intradermally into a groups of mice (n = 5) in a total volume of 50 mL saline. Mice were
anaesthetized and sacrificed after 3 h, the dorsal patch of skin tissue was removed and the injected spot was processed for histopathological studies
as described in materials and methods section. (A) Saline injected control section- note the intact ECM and the basement membrane surrounding the
blood vessels. (B) EC venom-injected section shows the extensive disorganized dermis and epidermis layers. (C) EC venom pre-incubated with
compound 5d (1:5; venom: compound; w/w) injected section shows restoration of normal basement membrane. Original magnification 40x. The inset
shows high power view of damaged and intact blood vessels.
doi:10.1371/journal.pone.0106364.g005
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prevented hemorrhage induced by EC venom; however protection
was found to be lesser extent in an independent injection
experiment.
So as to further delineate the microscopic alteration in dermis
and epidermis of skin tissues, EC venom in presence or absence of
compound injected spots were dissected out and processed for
histological examination (Fig. 5). PBS injected skin possessed an
intact basement membrane with no infiltration of inflammatory
leucocytes (Fig. 5A). The EC venom-injected skin sections
revealed an extensive degradation of ECM and basement
membrane surrounding the blood vessels along with infiltration
of inflammatory leucocytes (Fig. 5B). Pre-incubation of com-
pound 5d with venom did not show any dermonecrosis and
abolished the basement membrane degrading property of EC
venom (Fig. 5C). EC venom-induced blood vessels damage and
its restoration were ascertained by high resolution view of
corresponding skin sections (Fig. 5 insets). PBS injected skin
revealed intact blood vessels with no infiltration of inflammatory
leucocytes (Fig. 5A inset). In contrast, venom injected skin
revealed damaged blood vessels along with the infiltration of
inflammatory leucocytes (Fig. 5B inset). However, pre-incuba-
tion of venom with compound abrogated the blood vessels
degrading property of EC venom (Fig. 5C inset).
Effect of compound 5d on EC venom-induced
myonecrosis and myotoxicity
To further examine the protective efficacy of compound 5d on
EC venom-induced myonecrosis, both pre-incubation and inde-
pendent injection experiments were carried out. Experimental
mice were intramuscularly injected with either saline or EC
venom, and then the muscle tissue from the injection site was
dissected out 3 h post-injection. Saline injected muscle tissue
showed intact myofibrils with myocytes (Fig. 6A). EC venom
(5 mg) caused extensive myonecrosis of thigh muscle at the site of
injection. The histopathological observations of muscle tissue
sections injected with EC venom showed degraded and disordered
myofibrils along with ruptured myocytes (Fig. 6B). Pre-incubation
of EC venom with compound 5d effectively abrogated the muscle
degradation dose-dependently, and complete restoration of muscle
architecture was observed at 1:25 (venom: compound; w/w) ratio
(Fig. 6D).
Figure 6. Light microphotograph of mice skeletal muscle sections. EC venom (5 mg) was pre-incubated separately with various doses of
compound 5d (1:0; 1:5; 1:10 and 1:25; venom: compound; w/w) for 10 min at 37uC. The samples were injected intramuscularly into groups of mice
(n = 5) in a total volume of 50 mL saline. Mice were anaesthetized and sacrificed after 3 h, the muscle tissue from the injected site was removed and
processed for histopathological studies as described in materials and methods section. (A) Saline injected control section- note the intact basement
membrane with striated myofibrils (B) EC venom-injected section shows the extensive disorganized myofibroblasts with infiltration of inflammatory
leucocytes. (C)–(E) EC venom pre-incubated with the compound 5d injected section shows the inhibition and restoration of normal histology of
muscle tissue (with respective doses of 1:5; 1:10 and 1:25; venom: compound; w/w). (F) 150 mg Compound 5d alone injected section similar to saline
control. Original magnification 40x.
doi:10.1371/journal.pone.0106364.g006
Figure 7. Effect of compound 5d on EC venom induced
myotoxicity. EC venom (5 mg) was pre-incubated separately with
varied doses of compound 5d (1:0; 1:5; 1:10 and 1:25; venom:
compound; w/w) for 10 min at 37uC. The samples were injected
intramuscularly into group of mice (n = 5) in a total volume of 50 mL
saline. Mice were anaesthetized and sacrificed after 3 h and the assay
was performed as described in materials and methods section. Results
are expressed as mean 6 SEM of three independent experiments. ***
p,0.001, ** p,0.01, a - significant compared to saline control group
and b - significant compared to venom alone group.
doi:10.1371/journal.pone.0106364.g007
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Elevated serum LDH and CPK activities further confirmed the
EC venom-induced myotoxicity (Fig. 7). The compound 5d dose
dependently abrogated the augmented LDH and CPK activities in
pre-incubation experiment. On the other hand, independent
injection of compound 5d at 0 and 2.5 min showed significant
protection against myotoxicity but beyond 2.5 min it did not show
any protection (Table 3).
Effect of compound 5d on edema inducing activity of EC
venom
Furthermore to probe the inhibitory efficacy of compound 5d
against EC venom-induced edema, compound 5d treated EC
venom was injected to foot pads of experimental animals. EC
venom is well known to cause hemorrhagic edema, the extent of
edema was found to be 14265%. However, compound 5d failed
to hinder the edema formation caused by EC venom. However, it
abrogated the hemorrhage in the edematic paw in a dose
dependent manner and complete inhibition was observed at 1:5
ratio (venom: compound; w/w) (Table 4).
Effect of compound 5d on procoagulant activity of EC
venom
In order to examine the inhibitory effect of compound 5d on EC
venom-induced hemostasis alteration, recalcification time of
citrated plasma was determined. 0.5 mg of EC venom exhibited
potent procoagulant activity with clotting time of 45.068 sec,
which is highly significant when compared to normal clotting time
of 30065 sec. Conversely, procoagulant activity of EC venom
continued even with the increasing concentrations of compound
5d suggesting the inefficiency of compound 5d to inhibit the pro-
coagulant nature of EC venom (Table 5).
Effect of compound 5d on EC venom induced
fibrin(ogen)olytic activity
Further the inhibitory effect of compound 5d on EC venom-
induced fibrin(ogen)olytic activity was assessed, EC venom was
incubated with fibrin or fibrinogen in presence or absence of
compound 5d. EC venom (0.2 mg) specifically cleaved the a-
polymer and a-chain of the fibrin molecule, in contrast c-c dimer
and b-chain of the fibrin were found to be resistant to EC venom
(Fig. 8A). The a-polymer and a-chain degradation property of
EC venom on fibrin was dose dependently abrogated by
compound 5d and complete inhibition was observed at 1:25
(venom: compound; w/w) ratio. Further, EC venom specifically
cleaved Aa chain and Bb chain of fibrinogen but c chain was
resistant towards EC venom (Fig. 8B). The Aa and Bb chain
degradation property of EC venom was dose dependently
abrogated by compound 5d and complete inhibition was observed
at 1:50 (venom: compound; w/w) ratio. These results confirmed
that compound 5d largely prevented proteolytic activity of EC
venom as suggested by inhibitory action against degradation of
fibrin and fibrinogen.
Table 3. Effect of compound 5d on EC venom-induced serum LDH and CPK levels in experimental animals in an independent
injection experiment.
Groups (n=5) Delay in compound 5d administration (min) LDH (U/L) mean ± SEM CPK (U/L) mean ± SEM
Group I - Saline control - 230616 132612
Group II - Venom alone - 1058631a*** 566641a***
Group – III 0 312620 b*** 174626 b***
Group – IV 2.5 523623 b* 246621 b*
Group – V 5.0 743618 363624
Group – VI 7.5 956627 482632
Group – VII 10.0 1032628 554637
EC venom (5 mg) was intramuscularly injected to the group of mice (n = 5) followed by compound 5d (250 mg) injection at various time intervals (0, 2.5, 5, 7.5 and
10 min) to the same site where venom had been injected, and then the respective assay was performed as described in the materials and methods section. Data are
presented as the mean 6 SEM, *** p,0.001, * p,0.05, a - significant compared to saline control group and b - significant compared to venom alone group.
doi:10.1371/journal.pone.0106364.t003
Table 4. Effect of compound 5d on EC venom-induced edema activity.
Groups (n=5) Percent edema ratio mean ±SEM Visual rating for hemorrhage at right paw
Saline control 10162 -
Venom alone (3MED, 0.6 mg) 14265 a*** +++
Venom: Compound 5d (1:1, w/w) 13864` ++
Venom: Compound 5d (1:5, w/w) 14066` -
Venom: Compound 5d (1:10, w/w) 13966` -
Venom: Compound 5d (1:25, w/w) 13863` -
Compound 5d alone (15 mg) 10163 -
EC venom (0.6 mg) was pre-incubated with compound 5d at various doses and injected to the right food pad to groups of mice (n = 5) and then the respective assay was
performed as described in the materials and methods section. Data are presented as the mean 6 SEM, *** p,0.001, a - significant compared to saline control group
and ` - non-significant compared to venom alone group. The hemorrhage score is as follows: - nil; +++ High; ++ low.
doi:10.1371/journal.pone.0106364.t004
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UV-Visible spectral study
In order to investigate the possible interaction between
compound 5d and cations (Ca2+ and Zn 2+), UV-Vis spectra was
monitored. The spectra of compound 5d (1 mM) with different
concentration of CaCl2 and ZnCl2 (0–2 mM) were performed
independently (Fig. 9). Compound 5d showed maximal absorp-
tion between 220 and 230 nm, the unaffected absorption spectra
of compound 5d with increasing concentrations of CaCl2
(Fig. 9A) and ZnCl2 (Fig. 9B) revealed the absence of interaction
between compound and either of the cations.
Discussion
Snakebites still remain a neglected public health hazard and are
common environmental and occupational disease throughout the
world. Mortality rate due to snakebite is high in south Asia and
particularly, in India the yearly estimates range from 1,364 to
50,000 [1]. Even though the medically approved antivenom
therapy has drastically reduced the snakebite mortality rate, it does
not protect viper venom-induced local tissue damage. In many
instances, it has been a challenge to treat viper bite victims, which
leads to permanent disabilities. The viper bite-mediated local
toxicity is reported to be arbitrated by SVMPs [13,15,35]. Most of
the viperid venoms are known to compose at least 32% SVMPs
suggesting their potential role in viper bite pathology [36]. Thus,
effective inhibition of these enzymes is a key in the viper bite
management. The antivenom inability to offset viper venom-
induced local toxicity has been the basis for an insistent search for
SVMP inhibitors [37].
In the recent past, apigenin and its structural analogues are
shown to inhibit MMPs in target cells induced by several agents
such as carcinogens, ultraviolet A (UVA 320–400 nm), PMA, IL-
1b and TNF-a. They are also demonstrated to be potent anti-
cancer, anti-inflammatory and anti-bacterial agents [18–20].
Apigenin is known to mitigate a variety of anti-tumor effects, like
gap junctional and intracellular communication stimulation along
with inhibition of mutagenesis, transformation, angiogenesis and
tumorigenesis [21–23]. With this background, apigenin structural
analogues were synthesized using multi-component Ugi reaction.
Presently, Ugi reaction has received much attention due to its
simplicity and potentiality to synthesize desirable products with a
good yield [38]. Ugi is an example of domino reaction, which has
been used to convert a mixture of aldehyde, amine, carboxylic acid
and isonitrile into complex structures providing linear peptide like
adducts. These are important skeletal structures for the synthesis of
a number of medicinal and biologically important compounds
[39,40]. With this concern, the current study probed the
neutralizing efficacy of apigenin structural analogue (5d) on
Table 5. Effect of compound 5d on procoagulant activity of EC venom.
Groups (n=5) Plasma coagulation time (sec) mean ± SEM
CaCl2 alone 30065
Venom alone (0.5 mg) 4568a***
Venom: Compound 5d (1:1, w/w) 4466`
Venom: Compound 5d (1:5, w/w) 4965`
Venom: Compound 5d (1:10, w/w) 4764`
Venom: Compound 5d (1:25, w/w) 4467`
Venom: Compound 5d (1:50, w/w) 4766`
Compound 5d alone (50 mg) 29467
EC venom (0.6 mg) was pre-incubated with compound 5d at various doses and the procoagulant assay was performed as described in materials and methods section.
Data are presented as the mean 6 SEM, *** p,0.001, a - significant compared to saline control group and ` - non-significant compared to venom alone group.
doi:10.1371/journal.pone.0106364.t005
Figure 8. Effect of compound 5d on EC venom-induced fibrino(geno)lytic activity. EC venom (0.2 mg) was pre-incubated separately with
different doses of compound 5d (1:0; 1:1; 1:5; 1:10; 1:25 and 1:50; venom: compound; w/w; Lane 2–7 respectively, Lane-1 represents substrate alone
and Lane-8 represents substrate with 10 mg of compound 5d alone) for 10 min at 37uC. The reaction was initiated by adding respective substrates (A)
fibrin and (B) fibrinogen and incubated for 30 min. Samples were electrophoresed on 10% SDS-PAGE and the gels were processed as described in
materials and methods section.
doi:10.1371/journal.pone.0106364.g008
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SVMP-induced pharmacological effects both in pre-incubation as
well as independent injection experiments. In a similar study, we
previously reported the PLA2 and cholinesterase inhibitory
activities of novel isoxazolines and small oxazine compounds as
anti-tumor agent [41–43].
Several studies have reported many potential synthetic SVMP
inhibitors including Marimastat, CGS-270 23A, Bay-12 91566,
AG-3340, etc. However, there exists a constant quest for a broad
range of inhibitor effective against a range of SVMPs and crude
snake venoms [13,44]. Here, we demonstrate the ameliorative
efficacy of compound 5d on EC venom-induced hemorrhage in a
dose-dependent fashion suggesting its inhibitory action towards
SVMPs. This was further supported by the histological examina-
tion. Further, gelatin and casein zymography confirmed dose-
dependent abolition of the protease activity by compound 5d.
Since a decade, studies have reported anti-hemorrhagic and anti-
proteolytic efficacy of low molecular weight molecules (natural and
synthetic), which generally act by chelation of Zn2+ and
Ca2+cations. From the spectral results, it was very much clear
that compound 5d does not chelate either Zn2+ or Ca2+ to inhibit
SVMPs and serine proteases. However, it directly interacts with
the active site Glu146 via strong hydrogen bond, which in turn
connects with Ile142 and His145 and the other hydrophobic key
amino acids Val141, Ile168, Gly170, Pro171, Thr172, and Ile173
as suggested by molecular docking of compound 5d with
bothropasin. Having a non-chelating SVMP inhibitor is of great
advantage as it offers no toxicity by chelating Ca2+ along with
Zn2+ non-specifically as like EGTA, EDTA, TPEN, BAPTA,
clodronate and doxycycline [5,13,44]. Moreover, compound 5d
aligns at the top of this list as its efficacy falls in mM range similar
to batimastat, whereas the rest mentioned are effective at mM
range.
In addition, no effect on EC venom-induced procoagulant and
edema inducing activities (Ca2+ dependent) by compound 5d
suggests its inefficiency to chelate Ca2+ as evident by spectral
studies. Ecarin, a class III procoagulant metalloprotease is mainly
responsible for the pro-coagulant action of EC venom. Though P-
III class SVMPs is capable of producing hemorrhage, ecarin is a
non-hemorrhagic but a potent prothrombin activator [45]. Thus,
it can be stated that compound 5d neither chelates Ca2+ nor
inhibits ecarin. Nevertheless, compound 5d significantly attenuat-
ed the EC venom-induced fibrin and fibrinogen degradation,
which might be by directly interacting with the enzyme and not by
Ca2+ chelation. The ‘thrombin-like proteases’ present in EC
venom interrupts the coagulation cascade and specifically hydro-
lyzes the fibrinogen by either releasing fibrinopeptide A or B or
sometimes even both [46]. The fibrin monomers thus generated
endure limited polymerization due to the loss of fibrinopeptide(s).
Hence, fall short to activate factor VIII to VIIIa, which in turn
fails to crosslink the fibrin monomers to form a hard clot.
Consequently, compound 5d appears to be highly selective
towards SVMPs and serine proteases. Furthermore, the com-
pound 5d ameliorated the EC venom-induced myotoxicity and
tissue necrosis. The histopathology of EC venom-injected longi-
tudinal section of muscle tissue exhibited extensive necrosis, which
was restored in the presence of compound 5d. This was further
supported by the diminution of elevated serum levels of
cytoplasmic markers, such as CPK and LDH activities by
compound 5d to normal levels.
In conclusion, the current study undoubtedly revealed the
abrogation of EC venom-induced local manifestations such as
hemorrhage and persistent tissue necrosis by compound 5d, a
derivative having apigenin nucleus. It was demonstrated that
compound 5d selectively inhibits SVMPs both in silico and in vivo.
The molecular docking studies conferred the direct interaction of
compound 5d with P-III class SVMP bothropasin of B. jararaca at
the catalytic site but it does not chelate either Zn2+ or Ca2+. Thus,
compound 5d could be a primary agent in the management of
viper venom-induced local tissue damage, which can reduce
diffusion rate of systemic toxins in the snakebite victims. Hence,
the current investigation demonstrates that the compound can be
an effective auxiliary agent laterally with the existing antivenom
therapy in the management of viper bites. Future studies related to
protective efficacy of compound 5d against systemic hemorrhage
of vital organs and possible viper venom-induced secondary
complications including hormonal imbalance, renal malfunction,
and infertility, are highly exciting. In addition, a high degree of
structural and functional homology between SVMPs and MMPs
suggests that compound 5d may find enormous value in the
regulation of pathologies involving the participation of MMPs such
as cancer, wound healing, inflammation and arthritis.
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Figure 9. UV-VIS spectral studies of compound 5d in presence of CaCl2 and ZnCl2. The mixture of compound 5d (1 mM) and different
concentrations of (A) CaCl2 and (B) ZnCl2 (0–2.0 mM) in a final volume of 1 mL PBS. The samples were monitored by spectroscopic scanning with the
wavelength range of 200 to 300 nm.
doi:10.1371/journal.pone.0106364.g009
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